BioPharmSignal logoBioPharmSignal

Biotech News

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Olema Pharmaceuticals, Inc. (OLMA)Olema Pharmaceuticals, Inc.Earnings

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollment in the OPERA-02 pivotal Phase 3 trial of palazestrant in combination with ribociclib in patients

Related news

OLMAOlema Pharmaceuticals, Inc.2026-08-10 20:01 EST

Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

REGNRegeneron Pharmaceuticals2026-07-30 10:30 EST

Regeneron Reports Second Quarter 2026 Financial and Operating Results

REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

KURAKura Oncology2026-08-12 20:02 EST

Kura Oncology Reports Second Quarter 2026 Financial Results

KURAKura Oncology2026-08-05 11:30 EST

Kura Oncology to Report Second Quarter Financial Results

CHRSCoherus BioSciences, Inc.2026-07-22 17:36 EST

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

View all latest news

Olema Pharmaceuticals, Inc.

Endocrine-Driven Cancer Company Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer. Palazestrant Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast...

Recent company news

OLMAOlema Pharmaceuticals, Inc.2026-08-13 11:00 EST

Olema Oncology Appoints Jason O’Byrne as Chief Financial Officer

OLMAOlema Pharmaceuticals, Inc.2026-08-10 20:01 EST

Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

OLMAOlema Pharmaceuticals, Inc.2026-08-04 20:30 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMAOlema Pharmaceuticals, Inc.2026-07-02 20:30 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

OLMAOlema Pharmaceuticals, Inc.2026-06-02 20:30 EST

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
10.69 USD
Market cap
933.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States